Crossroads by Alantra

Paul Wardle led switches at HRA Pharma and Pfizer and worked on iconic switch brands such as Viagra, Advil, Lipitor and TUMS. Following up on our last episode on Rx-to-OTC Switches, Paul sheds lights on ACNU - the FDA's proposed rule on non-prescription drug products with additional conditions for non-prescriptive use. This is the FDA's 12-year effort in the works, aiming to empower consumers, foster stakeholder collaboration, and redefine access based on individual characteristics.

Explore the transformative journey of PointClickCare, a healthcare technology trailblazer inspired by Salesforce's success mantra. Overcoming skepticism, the company pioneered a seamless Software as a Service (SaaS) model in post-acute care, serving thousands of facilities. Strategic acquisitions and recent ventures, including Patient Pattern, demonstrate their commitment to innovative healthcare solutions in an evolving landscape. Mike Wessinger, Co-Founder of PointClickCare, joins Frederic Laurier at Alantra to discuss the growth journey of the company.

Paul Wardle led switches at HRA Pharma and Pfizer and worked on iconic switch brands such as Viagra, Advil, Lipitor and Opill. In light of recent Rx-to-OTC switches, Paul, who is now founder at Beacon Associates, shares his perspectives from his decade-long switch experience. In this episode, Rusty and Paul discussed the underlying impacts switch products bring to consumer adherence and utilization, as well as the switch process and the new ACNU regulation.

Collaboration between payers and providers has not only technological but also behavioral roadblocks. Dan Wilson, Founder & CEO of Moxe Health, joins Frederic Laurier at Alantra to discuss overcoming historical trust issues between the two, how he has built a purely digital business in a historically services-oriented Release of Information (ROI) subsector, the Datavant / Ciox merger, his provider subsidization model, and the importance of fast implementations in healthcare IT.

The concept of scoring and normalizing health assessments, similar to FICO in FinTech, is being explored to establish a global standard for health. Peter Ohnemus, serial entrepreneur and CEO & Founder of Dacadoo, joins Alantra to discuss how his design for digital health assessments aids dynamic pricing for Life & Health Insurance, and the importance of digital health engagement in a member's lifetime.

Healthcare data as we know it today is siloed. Ardy Arianpour, CEO & Co-Founder of SEQSTER, joins Frederic Laurier at Alantra to discuss data refinement, standardization, and tokenization to pull various data sources into one place, how a digital front door impacts clinical trial dropout rates, and opportunities to incorporate other sources of medical data in the future.

Gerianne DiPiano, founder and CEO of FemmePharma joins Rusty Ray to discuss Consumer and Healthcare Practitioner education around Women’s Health topics, as well as industry trends.

Like AWS and Azure did for cloud, BrightInsight is building the infrastructure needed for digital health solutions. Kal Patel, CEO of BrightInsight, joins Frederic Laurier at Alantra to discuss digital adoption within pharma and medical device companies, how digital solutions help reduce patient churn, FDA regulations regarding Software-as-a-Medical Device (SaMD), and BrightInsight’s spending strategy in the current fundraising environment.

Women’s Health is an emerging market, and one that is still largely undefined today. Topics like menopause, vaginal health, or sexual wellness are sometimes still considered Taboo and avoided in conversations.

Sally Mueller, Co-Founder of Womaness, a Women’s Health brand pioneering the menopause category, joins Alantra to discuss the founding of her company and how trends are shaping the industry.

Over the last decade, virtual care has witnessed explosive growth. Drew Turitz, SVP of Corporate Development at Teladoc, joins Frederic Laurier at Alantra to discuss the increasing adoption of telehealth, its acceptance by payors and providers, M&A as a strategy to enter new markets, acquisition opportunities in 2023, and the development of value-based care.